Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?

समान संसाधन

• First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
  द्वारा: Addeo, Alfredo, और अन्य
  प्रकाशित: (2018)
• ALK on my mind: alectinib takes an early lead in managing intracranial disease in non-small cell lung cancer with ALK rearrangements
  द्वारा: Tran, Phu N., और अन्य
  प्रकाशित: (2017)
• Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France
  द्वारा: Sivignon, Marine, और अन्य
  प्रकाशित: (2020)
• Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
  द्वारा: Wei, Jiacong, और अन्य
  प्रकाशित: (2018)
• Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer
  द्वारा: Uemura, Takehiro, और अन्य
  प्रकाशित: (2017)